|
1
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ettinger DS, Wood DE, Akerley W, Bazhenova
LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA,
Demmy TL, et al National comprehensive cancer network: Non-Small
Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw.
13:515–524. 2015.PubMed/NCBI
|
|
3
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Popper HH, Ryska A, Tímár J and Olszewski
W: Molecular testing in lung cancer in the era of precision
medicine. Transl Lung Cancer Res. 3:291–300. 2014.
|
|
5
|
Politi K and Herbst RS: Lung cancer in the
era of precision medicine. Clin Cancer Res. 21:2213–2220. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haberland M, Montgomery RL and Olson EN:
The many roles of histone deacetylases in development and
physiology: Implications for disease and therapy. Nat Rev Genet.
10:32–42. 2009. View
Article : Google Scholar
|
|
9
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duvic M, Olsen EA, Breneman D, Pacheco TR,
Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, et
al: Evaluation of the long-term tolerability and clinical benefit
of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Clin Lymphoma Myeloma. 9:412–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marks PA and Breslow R: Dimethyl sulfoxide
to vorinostat: Development of this histone deacetylase inhibitor as
an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen
BT and Ryningen A: Histone deacetylase inhibitors in cancer
treatment: A review of the clinical toxicity and the modulation of
gene expression in cancer cell. Curr Pharm Biotechnol. 8:388–400.
2007. View Article : Google Scholar
|
|
13
|
Marsoni S, Damia G and Camboni G: A work
in progress: The clinical development of histone deacetylase
inhibitors. Epigenetics. 3:164–171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaliszczak M, Trousil S, Åberg O, Perumal
M, Nguyen QD and Aboagye EO: A novel small molecule hydroxamate
preferentially inhibits HDAC6 activity and tumour growth. Br J
Cancer. 108:342–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Namdar M, Perez G, Ngo L and Marks PA:
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA
damage and sensitizes transformed cells to anticancer agents. Proc
Natl Acad Sci USA. 107:20003–20008. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krämer OH, Mahboobi S and Sellmer A:
Drugging the HDAC6-HSP90 interplay in malignanT cells. Trends
Pharmacol Sci. 35:501–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Li N, Caron C, Matthias G, Hess
D, Khochbin S and Matthias P: HDAC-6 interacts with and
deacetylates tubulin and microtubules in vivo. EMBO J.
22:1168–1179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park SJ, Kim JK, Bae HJ, Eun JW, Shen Q,
Kim HS, Shin WC, Yang HD, Lee EK, You JS, et al: HDAC6 sustains
growth stimulation by prolonging the activation of EGF receptor
through the inhibition of rabaptin-5-mediated early endosome fusion
in gastric cancer. Cancer Lett. 354:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aldana-Masangkay GI and Sakamoto KM: The
role of HDAC6 in cancer. J Biomed Biotechnol. 2011:8758242011.
View Article : Google Scholar
|
|
20
|
Kozikowski AP, Tapadar S, Luchini DN, Kim
KH and Billadeau DD: Use of the nitrile oxide cycloaddition (NOC)
reaction for molecular probe generation: A new class of enzyme
selective histone deacetylase inhibitors (HDACIs) showing picomolar
activity at HDAC6. J Med Chem. 51:4370–4373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y, Ran J, Liu M, Li D, Li Y, Shi X,
Meng D, Pan J, Ou G, Aneja R, et al: CYLD mediates ciliogenesis in
multiple organs by deubiquitinating Cep70 and inactivating HDAC6.
Cell Res. 24:1342–1353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ran J, Yang Y, Li D, Liu M and Zhou J:
Deacetylation of α-tubulin and cortactin is required for HDAC6 to
trigger ciliary disassembly. Sci Rep. 5:129172015. View Article : Google Scholar
|
|
23
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar
|
|
24
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deribe YL, Wild P, Chandrashaker A, Curak
J, Schmidt MH, Kalaidzidis Y, Milutinovic N, Kratchmarova I,
Buerkle L, Fetchko MJ, et al: Regulation of epidermal growth factor
receptor trafficking by lysine deacetylase HDAC6. Sci Signal.
2:ra842009.PubMed/NCBI
|
|
26
|
Gao YS, Hubbert CC and Yao TP: The
microtubule-associated histone deacetylase 6 (HDAC6) regulates
epidermal growth factor receptor (EGFR) endocytic trafficking and
degradation. J Biol Chem. 285:11219–11226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gradilone SA, Radtke BN, Bogert PS, Huang
BQ, Gajdos GB and LaRusso NF: HDAC6 inhibition restores ciliary
expression and decreases tumor growth. Cancer Res. 73:2259–2270.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dhanyamraju PK, Holz PS, Finkernagel F,
Fendrich V and Lauth M: Histone deacetylase 6 represents a novel
drug target in the oncogenic Hedgehog signaling pathway. Mol Cancer
Ther. 14:727–739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson
JB and Wang Z: HDAC6 regulates androgen receptor hypersensitivity
and nuclear localization via modulating Hsp90 acetylation in
castration-resistant prostate cancer. Mol Endocrinol. 23:1963–1972.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Haggarty SJ, Koeller KM, Wong JC,
Grozinger CM and Schreiber SL: Domain-selective small-molecule
inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin
deacetylation. Proc Natl Acad Sci USA. 100:4389–4394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaluza D, Kroll J, Gesierich S, Yao TP,
Boon RA, Hergenreider E, Tjwa M, Rössig L, Seto E, Augustin HG, et
al: Class IIb HDAC6 regulates endothelial cell migration and
angiogenesis by deacety-lation of cortactin. EMBO J. 30:4142–4156.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH,
Fidler IJ and Hung MC: Survival of cancer cells is maintained by
EGFR independent of its kinase activity. Cancer Cell. 13:385–393.
2008. View Article : Google Scholar : PubMed/NCBI
|
